Chronic hepatitis B: Update of recommendations

被引：372

作者：

Lok, ASF

McMahon, BJ

机构：

[1] Univ Michigan, Med Ctr, Div Gastroenterol, Ann Arbor, MI 48109 USA

[2] Ctr Dis Control, Alaska Nat Med Ctr, Viral Hepatitis Program, Anchorage, AK USA

[3] Ctr Dis Control, Arctic Invest Program, Anchorage, AK USA

来源：

HEPATOLOGY | 2004年 / 39卷 / 03期

关键词：

D O I：

10.1002/hep.20110

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

[No abstract available]

引用

页码：857 / 861

页数：5

共 19 条

[11] Effect of virological response on post-treatment durability of lamivudine-induced HBeAg seroconversion [J].

Lee, KM ;

Cho, SW ;

Kim, SW ;

Kim, HJ ;

Hahm, KB ;

Kim, JH .

JOURNAL OF VIRAL HEPATITIS, 2002, 9 (03) :208-212

[12]

Liaw YF, 2002, GASTROENTEROLOGY, V122, pA628

[13] Chronic hepatitis B [J].

Lok, ASF ;

McMahon, BJ .

HEPATOLOGY, 2001, 34 (06) :1225-1241

[14] Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B [J].

Marcellin, P ;

Chang, T ;

Lim, SG ;

Tong, MJ ;

Sievert, W ;

Shiffman, ML ;

Jeffers, L ;

Goodman, Z ;

Wulfsohn, MS ;

Xiong, S ;

Fry, J ;

Brosgart, CL ;

Afdhal, N ;

O'Conner, C ;

Andreone, P ;

Cursaro, C ;

Angus, P ;

Vaughan, R ;

Bain, V ;

Gutfreund, K ;

Barange, K ;

Duffant, M ;

Barnes, E ;

Bennett, M ;

Pressman, J ;

Bernstein, D ;

Bonino, F ;

Coco, B ;

Borum, M ;

Schuck, S ;

Bourliere, M ;

Benali, S ;

Boyer, N ;

Castelnau, C ;

Brown, R ;

Scales, S ;

Buggisch, P ;

Peterson, J ;

Cooksley, G ;

MacDonald, G ;

Couzigou, P ;

Foucner, D ;

Crawford, D ;

Der, A ;

Desmond, P ;

Boussioutas, A ;

DiBisceglie, A ;

Bacon, B ;

Dieterich, D ;

Goldman, D .

NEW ENGLAND JOURNAL OF MEDICINE, 2003, 348 (09) :808-816

[15] Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B [J].

Peters, MG ;

Hann, HW ;

Martin, P ;

Heathcote, EJ ;

Buggisch, P ;

Rubin, R ;

Bourliere, M ;

Kowdley, K ;

Trepo, C ;

Gray, DF ;

Sullivan, M ;

Kleber, K ;

Ebrahimi, R ;

Xiong, S ;

Brosgart, CL .

GASTROENTEROLOGY, 2004, 126 (01) :91-101

[16] Primary prophylaxis with lamivudine of hepatitis B virus reactivation in chronic HbsAg carriers with lymphoid malignancies treated with chemotherapy [J].

Rossi, G ;

Pelizzari, A ;

Motta, M ;

Puoti, M .

BRITISH JOURNAL OF HAEMATOLOGY, 2001, 115 (01) :58-62

[17] Adefovir dipivoxil therapy for lamivudine-resistant hepatitis B in pre- and post-liver transplantation patients [J].

Schiff, ER ;

Lai, CL ;

Hadziyannis, S ;

Neuhaus, P ;

Terrault, N ;

Colombo, M ;

Tillmann, HL ;

Samuel, D ;

Zeuzem, S ;

Lilly, L ;

Rendina, M ;

Villeneuve, JP ;

Lama, N ;

James, C ;

Wulfsohn, MS ;

Namini, H ;

Westland, C ;

Xiong, S ;

Choy, GS ;

Van Doren, S ;

Fry, J ;

Brosgart, CL ;

Shakil, AO ;

Fung, J ;

Alberti, A ;

Lok, A ;

Picciotto, A ;

Torre, F ;

Riely, C ;

Trepo, C ;

Poizollan, T ;

Botta-Fridlund, D ;

Gerolami, R ;

Douglas, D ;

Ranjan, D ;

Faust, D ;

Trojan, J ;

Gane, E ;

Villa, E ;

Boarino, V ;

Sokal, E ;

Starel, P ;

Bonino, F ;

Brunetto, M ;

Gordon, F ;

Pratt, J ;

Berr, F ;

Schiefke, I ;

McCaughan, G ;

Strasser, S .

HEPATOLOGY, 2003, 38 (06) :1419-1427

[18] Durability of HBeAg seroconversion following antiviral therapy for chronic hepatitis B:: relation to type of therapy and pretreatment serum hepatitis B virus DNA and alanine aminotransferase [J].

van Nunen, AB ;

Hansen, BE ;

Suh, DJ ;

Löhr, DJS ;

Chemello, L ;

Fontaine, H ;

Heathcote, J ;

Song, BC ;

Janssen, HLA ;

de Man, RA ;

Schalm, SW .

GUT, 2003, 52 (03) :420-424

[19] Is it safe to stop lamivudine after the emergence of YMDD mutants during lamivudine therapy for chronic hepatitis B? [J].

Wong, VWS ;

Chan, HLY ;

Wong, ML ;

Leung, N .

JOURNAL OF HEPATOLOGY, 2002, 36 :177-177

← 1 2 →